|
|
Post by notamnkdmillionaire on Aug 19, 2014 20:08:06 GMT -5
|
|
|
|
Post by goyocafe on Aug 19, 2014 21:21:46 GMT -5
It chaps my hide to read this, see the similarities, and then realize the drug had only completed Phase II when this deal was struck. Going to go shoot my dog now. |
|
|
|
Post by alcc on Aug 19, 2014 22:55:32 GMT -5
Close? NOT! What I've been saying: I am sure Al got the best deal he could; but a good/fair deal it is not.
|
|
|
|
Post by jpg on Aug 19, 2014 23:44:51 GMT -5
Not trying to be the Mannkind cheerleader here (I am starting to feel that way though!) but this deal is apples to chainsaws.
Why do I say that?
PCI-32765, a novel, oral, first-in-class Bruton's tyrosine kinase (Btk) inhibitor for the treatment of:
Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma
You know how many sales reps you need for this type of ultra specialized drug? Easily an order of magnitude less then you do to reach PCP (who don't treat any of the above mentioned patients). This is not the type of drug you would ever market to patients. Imagine a TV add for a Btk inhibitor... Marketing these drugs to a very restrained pool of specialist MD's isn't exactly the same as to a hundred million (or more) worldwide potential customers. The challenges are completely different. MM, CLL and NH lymphoma have some extremely different (but way cheaper) marketing challenges then diabetes.
This is a post phase 2 deal. The deal being done early isn't necessarily as good as people think since a lot can go wrong at multiple binary events along the way. I know a bit about BTK inhibitors but not enough to know if this will be the new Jakafi or whatever. They are walking into a much more crowded field then Jakafi or Gleevec did.
Time will tell but I will stick with MNKD...
JPG
|
|
